Dr. Richard Jeffrey Conner, MD

Dr. Richard Jeffrey Conner, MD is a Urologist at the Tri Valley Urology Medical Group in Murrieta, CA. Dr. Conner is both a Member of the American Urological Association and a Member of the Society of Government Service Urologist.
View Verified Reviews on Dr. *Set* DocName*

Dr. Richard Jeffrey Conner, MD

Locations
.............................................................................................................................................................

Dr. Richard Jeffrey Conner, MD

Education
.............................................................................................................................................................

Residency

Department of Urology

Naval Medical Center - San Diego

San Diego, CA

July 1991 - July 1996

Internship

Department of Obstetrics & Gynecology

Naval Medical Center - San Diego

San Diego, CA

June 1988 - June 1989

Graduate

Saint Louis University, School of Medicine, St. Louis, MO

M.D., 1988

Undergraduate

Point Loma College, San Diego, California

B.A. 1984 Major: Biology/Chemistry

Magna Cum Laude

Dr. Richard Jeffrey Conner, MD

Current Positions
.............................................................................................................................................................
  • 9/1998 - present: Partner Tri Valley Urology Medical Group, Murrieta, California 92562

Dr. Richard Jeffrey Conner, MD

Past Positions
.............................................................................................................................................................
  • 2005 - 2011 Governing Board Loma Linda University Medical Center - Murrieta
  • 10/2010 - 2011 Chief of Staff Loma Linda University Medical Center - Murrieta
  • 2004 - 2005 & 2006 - 2007 Chairman of Surgery Department, Inland Valley Medical Center, Rancho Springs Medical Center
  • 2002 - 2003 Vice Chair of Surgery Department Rancho Springs Medical Center
  • 2002 - 2003 Staff Urologist Clinical Instructor, Urology Residency; Naval Medical Center San Diego
  • 2002 - 2003 Staff Urologist USNS Mercy, Naval Hospital Ship

Dr. Richard Jeffrey Conner, MD

Operational Assignment
.............................................................................................................................................................
  • 7/1989 - 7/1991 General Medical Officer Assigned to: Commander Destroyer Squadron 5

Dr. Richard Jeffrey Conner, MD

Licensure / Certification
.............................................................................................................................................................
  • State of California, Medical License #G67933
  • National Board of Medical Examiners, 1989
  • American Board of Urology Certificate #2627

Dr. Richard Jeffrey Conner, MD

Professional Associations
.............................................................................................................................................................
  • Member American Urological Association
  • Member Society of Government Service Urologist
  • Fellow, American College of Surgeons

Dr. Richard Jeffrey Conner, MD

Hospital Privileges
.............................................................................................................................................................
  • Rancho Springs Medical Center, Murrieta, CA
  • Inland Valley Regional Medical Center, Wildomar, CA
  • Fallbrook Hospital, Fallbrook, CA

Dr. Richard Jeffrey Conner, MD

Honors and Awards
.............................................................................................................................................................
  • Dean's List 1980-1984
  • Who's Who in American Colleges and Universities, 1983
  • Magna Cum Laude, 1988
  • Lange Medical Award, 1988
  • Navy Achievement Medal, 1991
  • Winner, Academic Research Competition, NMCSD, 1994
  • Winner, ACMI Resident Scholarship at Western Section of AUA, 1994
  • Navy Achievement Medical, 1995
  • First runner-up, Academic Research Competition, NMCSD, 1996
  • Pfizer Scholar in Urology, 1997

Dr. Richard Jeffrey Conner, MD

Publications
.............................................................................................................................................................
  • Shellhamer, D.F., Conner, R.J., Richardson, R.E. and Heasley, V.L. "Fluorination of 1,3-dienes with Xenon Difluoride and (Di-fluoroiodo) Benzene." J. Of Org. Chem., 49:5015,1984.
  • Ward, J.F., Sands, J.P., Nowacki, M., Conner, R.J. and Huisman, T.K.: Malignant cytological washings from radical Prostatectomy specimens: A possible mechanism for local Recurrence of prostate cancer following surgical treatment of organ confined disease. J. Urol., 156:647,1996.

Dr. Richard Jeffrey Conner, MD

Professional Presentations (*presenting author)
.............................................................................................................................................................
  • *Conner, R.J. and Shellhamer, D.F. "Fluorination of 1,3-dienes with xenon difluoride and (difluoroiodo) benzene", American Chemical Society's 19th Western Regional Meeting, October,1983.
  • *Conner, R.J., Strand, W.R. and Sands, J.P., "Treatment of 2,8-dihydroxyadenine Urolithiasis in children using extracorporeal shock wave lithotripsy" (Abstract #7), 41st Annual James C. Kimbrough Urological Seminar, San Diego, CA, October 1993.
  • *Conner, R.J., Sands, J.P., Mostofi, F.K., Sesterhenn, I., "Relationship between perineural invasion on prostate needle biopsy and extra-prostatic extension of prostate cancer"(Abstract #236), 70th Annual Meeting of the Western Section of the AUA, Seattle, WA, August, 1994.
  • *Conner, R.J., Matthews, R.M. and Haluszka, M.M. "Large caliber suprapubic tube placement for long term bladder drainage" (Abstract #267). 70th Annual Meeting of the Western Section of AUA, Seattle, WA, August, 1994.
  • *Conner, R.J., Strand, W.R. and Sands, J.P., "Extracorporeal shock wave lithotripsy as primary therapy for 2,8-dihydroxyadenine urolithiasis" (Abstract #72). 70th Annual Meeting of the Western Section of the AUA, Seattle, WA, August 1994.
  • Huisman, T.K., Conner, R.J. and Sands, J.P., "Prostate specific antigen density (PSAD) and cancer detection if PSA is between 4 and 10: An algorithm to maximize detection rates" (Abstract #49). 71st Annual Meeting of the Western Section of the AUA, Scottsdale, AZ, November, 1995
  • *Conner, R.J., and Huisman, T.K., "Randomized prospective comparison of terazosin and doxazosin in the treatment of benign prostatic hyperplasia" (Abstract #70), 43rd Annual James C. Kimbrough Urological Seminar, Washington, D.C., December, 1995.
  • Ward, J.F., Sands, J.P., Nowacki, M., Conner, R.J. and Huisman, T.K., "Malignant cytological washings from radical prostatectomy specimens: A possible mechanism for local recurrence of prostate cancer following surgical treatment of organ confined disease" (Abstract #14), 43rd Annual James C. Kimbrough Urological Seminar, Washington, D.C., December 1995.

Dr. Richard Jeffrey Conner, MD

Research / Clinical Trials
.............................................................................................................................................................
  • Protocol P10-3 A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer Sponsored by Dendreon
  • Protocol CI-10-0009(a) Multi-center, prospective, randomized, double-blind, sham-controlled clinical study to evaluate safety and effectiveness of a transcutaneous, high-frequency, amplitude-modulated, non-invasive neuromodulation device on urgency urinary incontinence on subjects with overactive bladder Sponsored by Ethicon Endo-Surgery
  • Protocol FE 200486 CS30 A randomized, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) Sponsored by Ferring Pharmaceuticals
  • Protocol SIL1001 Principal Investigator A double-blind, placebo-controlled Study of Silodosin to Facilitate Urinary Stone Passage Sponsored by Watson Laboratories
  • Protocol A-10025 Evaluating the Psychometric Properties and Content Validity of the Peyronie's Disease Questionnaire (PDQ) Sponsored by Auxilium Pharmaceuticals